KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $29.4 billion.

  • Biogen's Liabilities and Shareholders Equity rose 495.63% to $29.4 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $115.0 billion, marking a year-over-year increase of 480.81%. This contributed to the annual value of $29.4 billion for FY2025, which is 495.63% up from last year.
  • As of Q4 2025, Biogen's Liabilities and Shareholders Equity stood at $29.4 billion, which was up 495.63% from $29.2 billion recorded in Q3 2025.
  • Biogen's 5-year Liabilities and Shareholders Equity high stood at $29.4 billion for Q4 2025, and its period low was $23.6 billion during Q1 2022.
  • Over the past 5 years, Biogen's median Liabilities and Shareholders Equity value was $25.9 billion (recorded in 2023), while the average stood at $26.2 billion.
  • As far as peak fluctuations go, Biogen's Liabilities and Shareholders Equity plummeted by 866.99% in 2021, and later skyrocketed by 1343.43% in 2023.
  • Over the past 5 years, Biogen's Liabilities and Shareholders Equity (Quarter) stood at $23.9 billion in 2021, then grew by 2.83% to $24.6 billion in 2022, then rose by 9.33% to $26.8 billion in 2023, then increased by 4.49% to $28.0 billion in 2024, then rose by 4.96% to $29.4 billion in 2025.
  • Its Liabilities and Shareholders Equity was $29.4 billion in Q4 2025, compared to $29.2 billion in Q3 2025 and $28.3 billion in Q2 2025.